<p>Doxorubicin (also known as Adriamycin) is widely used to treat various hematological malignancies and solid tumors. However, its most significant adverse effect is cardiotoxicity, which can lead to cardiac dysfunction and heart failure. The mechanisms behind doxorubicin-induced cardiotoxicity are complex, involving the generation of free radicals, peroxynitrite production, calcium dysregulation, mitochondrial damage, and disruptions in apoptotic and autophagic pathways. Taurine, a naturally occurring sulfated amino acid, plays a crucial role in maintaining cellular functions and protecting tissues. Recent studies suggest that taurine co-administration may mitigate the cardiotoxic effects of doxorubicin. The objective of this review is to explore the mechanisms by which taurine exerts its protective effects against doxorubicin-induced cardiac damage. A comprehensive literature search was conducted through Google Scholar, EBSCO, Embase, Medline, and Science Direct to identify relevant studies that support taurine’s role in protecting against doxorubicin-induced cardiac injury. Multiple preclinical and some clinical studies have demonstrated that taurine possesses potential protective effects against cardiac injury induced by various drugs, including doxorubicin. Gaining a deeper understanding of the mechanisms contributing to doxorubicin-induced cardiac failure will provide insights into the cardioprotective properties of taurine, highlighting its potential clinical applications for preventing or reducing doxorubicin-induced heart damage.</p>